Alpha Tau is turning diffusing alpha radiation into an equipment-light, potentially paradigm-shifting solid-tumor therapy—now racing a binary FDA path while scaling a fragile, moat-like isotope supply chain.
Overview
Alpha Tau Medical (DRTS) is a clinical-stage Israeli oncology therapeutics company developing Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a localized radiotherapy platform designed to deliver the high cell-killing potency of alpha particles inside solid tumors while sparing surrounding healthy tissue. The platform uses Radium-224-coated metal “seeds” whose radioactive daughter atoms diffuse several millimeters through the tumor, overcoming alpha particles’ traditional sub-100-micron range limitation and enabling conformal tumor coverage. The company targets high-unmet-need indications including cutaneous squamous cell carcinoma, pancreatic ductal adenocarcinoma, glioblastoma, recurrent head & neck cancer, and prostate recurrence after EBRT. Commercially, Alpha Tau is largely pre-revenue in major markets such as the U.S., with limited early revenue in Israel, but it is positioned for a step-change following Japan’s marketing approval (Feb 2026) for unresectable locally advanced or recurrent head & neck cancer. Revenue is expected primarily from recurring sales of sterile disposable radioactive sources and proprietary applicators, with future contributions from planning software and manufacturing/logistics services. The customer base centers on academic medical centers, cancer hospitals, and oncology practices seeking superior efficacy in resistant/hypoxic tumors with an equipment-light outpatient workflow.